View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNova Cannabis 将来の成長Future 基準チェック /06現在、 Nova Cannabisの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Specialty Retail 収益成長29.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Breakeven Date Change • Aug 15Forecast to breakeven in 2024The analyst covering Nova Cannabis expects the company to break even for the first time. New forecast suggests the company will make a profit of CA$2.00m in 2024. Average annual earnings growth of 89% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • Oct 22SNDL Completes Privatization of Nova Cannabis and Nova Shares Expected to be Delisted from the Toronto Stock Exchange and the OTC MarketsSNDL Inc. (‘SNDL’) and Nova Cannabis Inc. (‘Nova’) announced the closing of the previously announced plan of arrangement (the ‘Arrangement’) pursuant to which SNDL has acquired all of the issued and outstanding common shares in the capital of Nova (‘Nova Shares’) not already owned by SNDL, representing approximately 34.8% of the Nova Shares. The Arrangement was approved by at least two-thirds of the holders of Nova Shares (‘Nova Shareholders’) and the majority of disinterested Nova Shareholders under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions at a special meeting of the Nova Shareholders on October 16, 2024. The Court of King's Bench of Alberta granted a final order approving the Arrangement on October 17, 2024. The Nova Shares are expected to be delisted from the TSX and the OTC Markets. Following the delisting of the Nova Shares, Nova intends to submit an application to cease to be a reporting issuer in each applicable jurisdiction of Canada pursuant to applicable securities laws, and, following which, SNDL intends to amalgamate with Nova pursuant to the provisions of the Business Corporations Act (Alberta). Registered holders of Nova Shares are reminded that they must send their completed and executed letter of transmittal and election form and related share certificates or DRS advices, if any, to the depository for the Arrangement, Odyssey Trust Company, as soon as possible in order to receive the Consideration to which they are entitled under the Arrangement.お知らせ • Aug 13Nova Shares to Be Delisted from the TSXSNDL Inc. ("SNDL") and Nova Cannabis Inc. ("Nova") announced that they have entered into an arrangement agreement (the "Agreement") pursuant to which SNDL will acquire all of the issued and outstanding common shares in the capital of Nova ("Nova Shares") not already owned by SNDL, representing approximately 34.8% of Nova Shares, by way of a statutory plan of arrangement (the "Transaction") for aggregate consideration of approximately $40 million (the "Consideration"). The Transaction has been approved by the boards of directors of both SNDL and Nova and is expected to close on or before October 18, 2024. Following the closing of the Transaction, the Nova Shares are expected to be delisted from the TSX and Nova will apply to cease to be a reporting issuer in all provinces and territories of Canada.Reported Earnings • Aug 04Second quarter 2024 earnings released: EPS: CA$0.01 (vs CA$0.018 in 2Q 2023)Second quarter 2024 results: EPS: CA$0.01 (down from CA$0.018 in 2Q 2023). Revenue: CA$69.2m (up 8.1% from 2Q 2023). Net income: CA$859.0k (down 17% from 2Q 2023). Profit margin: 1.2% (down from 1.6% in 2Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.9% growth forecast for the Specialty Retail industry in Germany. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.お知らせ • Jul 20Nova Cannabis Inc. to Report Q2, 2024 Results on Aug 01, 2024Nova Cannabis Inc. announced that they will report Q2, 2024 results After-Market on Aug 01, 2024お知らせ • Jul 16Nova Cannabis Inc. Announces Chief Executive Officer Changes, Effective August 1, 2024Nova Cannabis Inc. announced that Marcie Kiziak, Chief Executive Officer and a Director of Nova, will be stepping down from her role of Chief Executive Officer, effective August 1, 2024. Ms. Kiziak will continue to serve as a Director of Nova until second quarter 2024 financial results are announced. This decision comes in connection with the restructuring announced by SNDL Inc. earlier July 16, 2024. Ms. Kiziak successfully led Nova through the early years of Canadian federal legalization and worked to build a unique and highly disruptive discount strategy in Cannabis retail. Nova's success prompted a number of retail operators to follow suit, bringing greater value and convenience to consumers. Under her leadership, the Nova team has grown the Value Buds portfolio to more than 100 stores through a combination of organic and inorganic growth. Taking the reins as Interim Chief Executive Officer will be Grant Sanderson, Nova's current Chief Operating Officer. Sanderson's appointment will take effect upon Ms. Kiziak's departure.お知らせ • May 17Nova Cannabis Inc., Annual General Meeting, Jun 20, 2024Nova Cannabis Inc., Annual General Meeting, Jun 20, 2024.New Risk • May 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (8.6% increase in shares outstanding). Market cap is less than US$100m (€51.6m market cap, or US$56.1m).Reported Earnings • May 09First quarter 2024 earnings released: CA$0.01 loss per share (vs CA$0.01 loss in 1Q 2023)First quarter 2024 results: CA$0.01 loss per share (in line with 1Q 2023). Revenue: CA$64.3m (up 6.8% from 1Q 2023). Net loss: CA$333.0k (loss narrowed 39% from 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 5.4% growth forecast for the Specialty Retail industry in Germany. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.お知らせ • May 01Nova Cannabis Inc. to Report Q1, 2024 Results on May 07, 2024Nova Cannabis Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024Reported Earnings • Mar 27Full year 2023 earnings released: EPS: CA$0.05 (vs CA$0.20 loss in FY 2022)Full year 2023 results: EPS: CA$0.05 (up from CA$0.20 loss in FY 2022). Revenue: CA$259.3m (up 14% from FY 2022). Net income: CA$3.03m (up CA$14.2m from FY 2022). Profit margin: 1.2% (up from net loss in FY 2022). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Specialty Retail industry in Germany. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.お知らせ • Mar 13Nova Cannabis Inc. to Report Q4, 2023 Results on Mar 25, 2024Nova Cannabis Inc. announced that they will report Q4, 2023 results After-Market on Mar 25, 2024Reported Earnings • Nov 10Third quarter 2023 earnings released: EPS: CA$0.04 (vs CA$0.027 loss in 3Q 2022)Third quarter 2023 results: EPS: CA$0.04 (up from CA$0.027 loss in 3Q 2022). Revenue: CA$67.7m (up 15% from 3Q 2022). Net income: CA$2.10m (up CA$3.63m from 3Q 2022). Profit margin: 3.1% (up from net loss in 3Q 2022).お知らせ • Nov 01Nova Cannabis Inc. to Report Q3, 2023 Results on Nov 08, 2023Nova Cannabis Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023Reported Earnings • Aug 11Second quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.024 loss in 2Q 2022)Second quarter 2023 results: EPS: CA$0.02 (up from CA$0.024 loss in 2Q 2022). Revenue: CA$64.0m (up 14% from 2Q 2022). Net income: CA$1.04m (up CA$2.41m from 2Q 2022). Profit margin: 1.6% (up from net loss in 2Q 2022).お知らせ • Aug 04Nova Cannabis Inc. to Report Q2, 2023 Results on Aug 09, 2023Nova Cannabis Inc. announced that they will report Q2, 2023 results After-Market on Aug 09, 2023Reported Earnings • May 12First quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.062 loss in 1Q 2022)First quarter 2023 results: CA$0.01 loss per share (improved from CA$0.062 loss in 1Q 2022). Revenue: CA$60.2m (up 21% from 1Q 2022). Net loss: CA$544.0k (loss narrowed 85% from 1Q 2022).お知らせ • May 05Nova Cannabis Inc. to Report Q1, 2023 Results on May 10, 2023Nova Cannabis Inc. announced that they will report Q1, 2023 results After-Market on May 10, 2023Reported Earnings • Mar 30Full year 2022 earnings released: CA$0.20 loss per share (vs CA$0.39 loss in FY 2021)Full year 2022 results: CA$0.20 loss per share (improved from CA$0.39 loss in FY 2021). Revenue: CA$226.4m (up 69% from FY 2021). Net loss: CA$11.2m (loss narrowed 46% from FY 2021). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Specialty Retail industry in Germany.Board Change • Nov 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Director Ron Hozjan is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Nov 09Third quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2021)Third quarter 2022 results: CA$0.03 loss per share (improved from CA$0.11 loss in 3Q 2021). Revenue: CA$58.9m (up 52% from 3Q 2021). Net loss: CA$1.54m (loss narrowed 75% from 3Q 2021). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Specialty Retail industry in Germany.Breakeven Date Change • Aug 15Forecast to breakeven in 2024The analyst covering Nova Cannabis expects the company to break even for the first time. New forecast suggests the company will make a profit of CA$2.00m in 2024. Average annual earnings growth of 89% is required to achieve expected profit on schedule.Reported Earnings • Aug 13Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: CA$56.3m (up 90% from 2Q 2021). Net loss: CA$1.37m (loss narrowed 81% from 2Q 2021). Over the next year, revenue is forecast to grow 38%, compared to a 11% growth forecast for the industry in Germany.Reported Earnings • May 11First quarter 2022 earnings released: CA$0.06 loss per share (vs CA$0.058 loss in 1Q 2021)First quarter 2022 results: CA$0.06 loss per share (down from CA$0.058 loss in 1Q 2021). Revenue: CA$49.8m (up 171% from 1Q 2021). Net loss: CA$3.53m (loss widened 59% from 1Q 2021). Over the next year, revenue is forecast to grow 91%, compared to a 12% growth forecast for the industry in Germany.Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Ron Hozjan is the most experienced director on the board, commencing their role in 2018. Lead Independent Director Anne Fitzgerald was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Aug 18Second quarter 2021 earnings released: CA$0.12 loss per share (vs CA$0.10 profit in 2Q 2020)The company reported a mediocre second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CA$29.7m (up 86% from 2Q 2020). Net loss: CA$7.02m (down CA$8.40m from profit in 2Q 2020). このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Nova Cannabis は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:2LK - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202426931215N/A3/31/202426331316N/A12/31/20232593912N/A9/30/2023253-269N/A6/30/2023244-637N/A3/31/2023237-8-24N/A12/31/2022226-11-80N/A9/30/2022213-12-13-3N/A6/30/2022192-16-22-7N/A3/31/2022166-22-27-13N/A12/31/2021134-21-22-10N/A9/30/2021104-19-18-8N/A6/30/202181-11-8-5N/A3/31/202166-4-12N/A12/31/202063-2411N/A9/30/202059-3513N/A12/31/201941-928N/A12/31/201810-11313N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 2LKの予測収益成長が 貯蓄率 ( 0.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 2LKの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 2LKの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 2LKの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 2LKの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 2LKの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YRetail 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/10/21 23:24終値2024/10/21 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nova Cannabis Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Frederico Yokota Choucair GomesATB Cormark
Breakeven Date Change • Aug 15Forecast to breakeven in 2024The analyst covering Nova Cannabis expects the company to break even for the first time. New forecast suggests the company will make a profit of CA$2.00m in 2024. Average annual earnings growth of 89% is required to achieve expected profit on schedule.
お知らせ • Oct 22SNDL Completes Privatization of Nova Cannabis and Nova Shares Expected to be Delisted from the Toronto Stock Exchange and the OTC MarketsSNDL Inc. (‘SNDL’) and Nova Cannabis Inc. (‘Nova’) announced the closing of the previously announced plan of arrangement (the ‘Arrangement’) pursuant to which SNDL has acquired all of the issued and outstanding common shares in the capital of Nova (‘Nova Shares’) not already owned by SNDL, representing approximately 34.8% of the Nova Shares. The Arrangement was approved by at least two-thirds of the holders of Nova Shares (‘Nova Shareholders’) and the majority of disinterested Nova Shareholders under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions at a special meeting of the Nova Shareholders on October 16, 2024. The Court of King's Bench of Alberta granted a final order approving the Arrangement on October 17, 2024. The Nova Shares are expected to be delisted from the TSX and the OTC Markets. Following the delisting of the Nova Shares, Nova intends to submit an application to cease to be a reporting issuer in each applicable jurisdiction of Canada pursuant to applicable securities laws, and, following which, SNDL intends to amalgamate with Nova pursuant to the provisions of the Business Corporations Act (Alberta). Registered holders of Nova Shares are reminded that they must send their completed and executed letter of transmittal and election form and related share certificates or DRS advices, if any, to the depository for the Arrangement, Odyssey Trust Company, as soon as possible in order to receive the Consideration to which they are entitled under the Arrangement.
お知らせ • Aug 13Nova Shares to Be Delisted from the TSXSNDL Inc. ("SNDL") and Nova Cannabis Inc. ("Nova") announced that they have entered into an arrangement agreement (the "Agreement") pursuant to which SNDL will acquire all of the issued and outstanding common shares in the capital of Nova ("Nova Shares") not already owned by SNDL, representing approximately 34.8% of Nova Shares, by way of a statutory plan of arrangement (the "Transaction") for aggregate consideration of approximately $40 million (the "Consideration"). The Transaction has been approved by the boards of directors of both SNDL and Nova and is expected to close on or before October 18, 2024. Following the closing of the Transaction, the Nova Shares are expected to be delisted from the TSX and Nova will apply to cease to be a reporting issuer in all provinces and territories of Canada.
Reported Earnings • Aug 04Second quarter 2024 earnings released: EPS: CA$0.01 (vs CA$0.018 in 2Q 2023)Second quarter 2024 results: EPS: CA$0.01 (down from CA$0.018 in 2Q 2023). Revenue: CA$69.2m (up 8.1% from 2Q 2023). Net income: CA$859.0k (down 17% from 2Q 2023). Profit margin: 1.2% (down from 1.6% in 2Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.9% growth forecast for the Specialty Retail industry in Germany. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
お知らせ • Jul 20Nova Cannabis Inc. to Report Q2, 2024 Results on Aug 01, 2024Nova Cannabis Inc. announced that they will report Q2, 2024 results After-Market on Aug 01, 2024
お知らせ • Jul 16Nova Cannabis Inc. Announces Chief Executive Officer Changes, Effective August 1, 2024Nova Cannabis Inc. announced that Marcie Kiziak, Chief Executive Officer and a Director of Nova, will be stepping down from her role of Chief Executive Officer, effective August 1, 2024. Ms. Kiziak will continue to serve as a Director of Nova until second quarter 2024 financial results are announced. This decision comes in connection with the restructuring announced by SNDL Inc. earlier July 16, 2024. Ms. Kiziak successfully led Nova through the early years of Canadian federal legalization and worked to build a unique and highly disruptive discount strategy in Cannabis retail. Nova's success prompted a number of retail operators to follow suit, bringing greater value and convenience to consumers. Under her leadership, the Nova team has grown the Value Buds portfolio to more than 100 stores through a combination of organic and inorganic growth. Taking the reins as Interim Chief Executive Officer will be Grant Sanderson, Nova's current Chief Operating Officer. Sanderson's appointment will take effect upon Ms. Kiziak's departure.
お知らせ • May 17Nova Cannabis Inc., Annual General Meeting, Jun 20, 2024Nova Cannabis Inc., Annual General Meeting, Jun 20, 2024.
New Risk • May 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (8.6% increase in shares outstanding). Market cap is less than US$100m (€51.6m market cap, or US$56.1m).
Reported Earnings • May 09First quarter 2024 earnings released: CA$0.01 loss per share (vs CA$0.01 loss in 1Q 2023)First quarter 2024 results: CA$0.01 loss per share (in line with 1Q 2023). Revenue: CA$64.3m (up 6.8% from 1Q 2023). Net loss: CA$333.0k (loss narrowed 39% from 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 5.4% growth forecast for the Specialty Retail industry in Germany. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
お知らせ • May 01Nova Cannabis Inc. to Report Q1, 2024 Results on May 07, 2024Nova Cannabis Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024
Reported Earnings • Mar 27Full year 2023 earnings released: EPS: CA$0.05 (vs CA$0.20 loss in FY 2022)Full year 2023 results: EPS: CA$0.05 (up from CA$0.20 loss in FY 2022). Revenue: CA$259.3m (up 14% from FY 2022). Net income: CA$3.03m (up CA$14.2m from FY 2022). Profit margin: 1.2% (up from net loss in FY 2022). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Specialty Retail industry in Germany. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
お知らせ • Mar 13Nova Cannabis Inc. to Report Q4, 2023 Results on Mar 25, 2024Nova Cannabis Inc. announced that they will report Q4, 2023 results After-Market on Mar 25, 2024
Reported Earnings • Nov 10Third quarter 2023 earnings released: EPS: CA$0.04 (vs CA$0.027 loss in 3Q 2022)Third quarter 2023 results: EPS: CA$0.04 (up from CA$0.027 loss in 3Q 2022). Revenue: CA$67.7m (up 15% from 3Q 2022). Net income: CA$2.10m (up CA$3.63m from 3Q 2022). Profit margin: 3.1% (up from net loss in 3Q 2022).
お知らせ • Nov 01Nova Cannabis Inc. to Report Q3, 2023 Results on Nov 08, 2023Nova Cannabis Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023
Reported Earnings • Aug 11Second quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.024 loss in 2Q 2022)Second quarter 2023 results: EPS: CA$0.02 (up from CA$0.024 loss in 2Q 2022). Revenue: CA$64.0m (up 14% from 2Q 2022). Net income: CA$1.04m (up CA$2.41m from 2Q 2022). Profit margin: 1.6% (up from net loss in 2Q 2022).
お知らせ • Aug 04Nova Cannabis Inc. to Report Q2, 2023 Results on Aug 09, 2023Nova Cannabis Inc. announced that they will report Q2, 2023 results After-Market on Aug 09, 2023
Reported Earnings • May 12First quarter 2023 earnings released: CA$0.01 loss per share (vs CA$0.062 loss in 1Q 2022)First quarter 2023 results: CA$0.01 loss per share (improved from CA$0.062 loss in 1Q 2022). Revenue: CA$60.2m (up 21% from 1Q 2022). Net loss: CA$544.0k (loss narrowed 85% from 1Q 2022).
お知らせ • May 05Nova Cannabis Inc. to Report Q1, 2023 Results on May 10, 2023Nova Cannabis Inc. announced that they will report Q1, 2023 results After-Market on May 10, 2023
Reported Earnings • Mar 30Full year 2022 earnings released: CA$0.20 loss per share (vs CA$0.39 loss in FY 2021)Full year 2022 results: CA$0.20 loss per share (improved from CA$0.39 loss in FY 2021). Revenue: CA$226.4m (up 69% from FY 2021). Net loss: CA$11.2m (loss narrowed 46% from FY 2021). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Specialty Retail industry in Germany.
Board Change • Nov 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Director Ron Hozjan is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Nov 09Third quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2021)Third quarter 2022 results: CA$0.03 loss per share (improved from CA$0.11 loss in 3Q 2021). Revenue: CA$58.9m (up 52% from 3Q 2021). Net loss: CA$1.54m (loss narrowed 75% from 3Q 2021). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Specialty Retail industry in Germany.
Breakeven Date Change • Aug 15Forecast to breakeven in 2024The analyst covering Nova Cannabis expects the company to break even for the first time. New forecast suggests the company will make a profit of CA$2.00m in 2024. Average annual earnings growth of 89% is required to achieve expected profit on schedule.
Reported Earnings • Aug 13Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: CA$56.3m (up 90% from 2Q 2021). Net loss: CA$1.37m (loss narrowed 81% from 2Q 2021). Over the next year, revenue is forecast to grow 38%, compared to a 11% growth forecast for the industry in Germany.
Reported Earnings • May 11First quarter 2022 earnings released: CA$0.06 loss per share (vs CA$0.058 loss in 1Q 2021)First quarter 2022 results: CA$0.06 loss per share (down from CA$0.058 loss in 1Q 2021). Revenue: CA$49.8m (up 171% from 1Q 2021). Net loss: CA$3.53m (loss widened 59% from 1Q 2021). Over the next year, revenue is forecast to grow 91%, compared to a 12% growth forecast for the industry in Germany.
Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director Ron Hozjan is the most experienced director on the board, commencing their role in 2018. Lead Independent Director Anne Fitzgerald was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Aug 18Second quarter 2021 earnings released: CA$0.12 loss per share (vs CA$0.10 profit in 2Q 2020)The company reported a mediocre second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CA$29.7m (up 86% from 2Q 2020). Net loss: CA$7.02m (down CA$8.40m from profit in 2Q 2020).